Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection
Public ClinicalTrials.gov record NCT00612898. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b/3, Randomized, Double Blind, Dose Confirming Study of the Safety, Efficacy and Tolerability of Apricitabine Versus Lamivudine in Treatment-experienced HIV-1 Infected Patients With the M184V/I Mutation in Reverse Transcriptase
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Apricitabine is a new NRTI which is active against drug-resistant HIV. NRTIs are often included as part of patients' treatment, but many HIV-infected patients develop resistance to commonly used NRTIs such as lamivudine (3TC) and emtricitabine (FTC). This study will examine whether including apricitabine as part of patients' treatment is more effective than including lamivudine,when patients change treatment because of drug resistance.
Study identification
- NCT ID
- NCT00612898
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 239 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2008 (Type not available)
- Primary completion
- Jan 2010 (Actual)
- Completion
- Jan 2010 (Actual)
- Last update posted
- Jan 23, 2012
2008 – 2010
United States locations
- U.S. sites
- 33
- U.S. states
- 16
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UAB, 845 19th St South, South Beville Biomedical Research Building | Birmingham | Alabama | 35294-2170 | — |
| University of Alabama at Birmingham | Birmingham | Alabama | 35294-2170 | — |
| Southwest Center for HIV/AIDS | Phoenix | Arizona | 85006 | — |
| Living Hope Clinical Foundation, Inc | Long Beach | California | 90813 | — |
| Kaiser Permanente Medical Center | San Francisco | California | 94115 | — |
| AIDS Research Alliance | West Hollywood | California | 90069 | — |
| Denver Health & Hospital Authority | Denver | Colorado | 80204 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20007 | — |
| George Washington University | Washington D.C. | District of Columbia | 20037 | — |
| Gary Richmond, MD | Fort Lauderdale | Florida | 33316 | — |
| Orlando Immunology Center | Orlando | Florida | 32803 | — |
| Infectious Disease Research Institute, Inc | Tampa | Florida | 33614 | — |
| Treasure Coast Infectious Diseases Consultants | Vero Beach | Florida | 32960 | — |
| Aids Research Consortium Of Atlanta Inc. | Atlanta | Georgia | 30308 | — |
| Atlanta Infectious Disease Group, PC | Atlanta | Georgia | 30309 | — |
| University of Hawaii | Honolulu | Hawaii | 96816-2333 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| University of Kansas School of Medicine | Wichita | Kansas | 67214 | — |
| Fenway Community Health Center | Boston | Massachusetts | 02115 | — |
| Community Research Intiative of New England | Boston | Massachusetts | 02215-3319 | — |
| I.D. Care, Inc. | Hillsborough | New Jersey | 08844-4254 | — |
| Saint Michael's Medical Center | Newark | New Jersey | 07102 | — |
| Summa Health System | Akron | Ohio | 44304-1430 | — |
| The Research & Education Institute | Portland | Oregon | 97209 | — |
| Central Texas Clinical Research | Austin | Texas | 78705 | — |
| Nicholaos C Bellos, MD, PA | Dallas | Texas | 75204 | — |
| North Texas Infectious Diseases Consultants, P.A. | Dallas | Texas | 75246 | — |
| Tarrant County Infection Disease Associates | Fort Worth | Texas | 76104 | — |
| University of Texas Medical Brach | Galveston | Texas | 77555-0435 | — |
| Therapeutic Concepts | Houston | Texas | 77004 | — |
| Resarch Access Network | Houston | Texas | 77098 | — |
| DCOL Center for Clinical Research | Longview | Texas | 75605 | — |
| Swedish Medical Center | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 67 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00612898, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 23, 2012 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00612898 live on ClinicalTrials.gov.